Abiraterone acetate/niraparib - Janssen
Alternative Names: AKEEGA; CJNJ-67652000Latest Information Update: 23 Dec 2025
At a glance
- Originator Janssen
- Class Androstenols; Antiandrogens; Antineoplastics; Benzamides; Indazoles; Phenanthrenes; Piperidines; Pyridines; Small molecules
- Mechanism of Action CYP17A1 protein inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
Most Recent Events
- 12 Dec 2025 Registered for Prostate cancer (Combination therapy, Metastatic disease) in USA (PO)
- 12 Dec 2025 Efficacy and adverse events data from the phase III AMPLITUDE trial in BRCA2-mutated metastatic castration-sensitive Prostate cancer released by Johnson & Johnson
- 03 Nov 2025 Launched for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in Denmark (PO)